| Primary |
| Chronic Myeloid Leukaemia |
53.3% |
| Acute Lymphocytic Leukaemia |
23.0% |
| Prophylaxis |
6.9% |
| Leukaemia |
2.4% |
| Acute Myeloid Leukaemia |
2.1% |
| B Precursor Type Acute Leukaemia |
2.1% |
| Infection |
1.9% |
| Hypertension |
1.8% |
| Acute Lymphocytic Leukaemia Recurrent |
1.0% |
| Infection Prophylaxis |
0.8% |
| Blast Crisis In Myelogenous Leukaemia |
0.7% |
| Pain |
0.6% |
| Insomnia |
0.5% |
| Constipation |
0.5% |
| Gastrooesophageal Reflux Disease |
0.5% |
| Cardiac Failure |
0.4% |
| Nausea |
0.4% |
| Anxiety |
0.3% |
| Asthma |
0.3% |
| Depression |
0.3% |
|
| Pleural Effusion |
19.2% |
| Death |
10.2% |
| White Blood Cell Count Decreased |
9.4% |
| Headache |
6.2% |
| Rash |
5.6% |
| Nausea |
4.6% |
| Vomiting |
4.6% |
| Pyrexia |
4.1% |
| Thrombocytopenia |
3.8% |
| Adverse Event |
3.7% |
| Malignant Neoplasm Progression |
3.4% |
| Pulmonary Oedema |
3.3% |
| Neoplasm Malignant |
3.2% |
| Weight Increased |
3.2% |
| Diarrhoea |
2.9% |
| Fatigue |
2.9% |
| Pneumonia |
2.6% |
| Weight Decreased |
2.5% |
| Drug Dose Omission |
2.4% |
| Respiratory Failure |
2.3% |
|
| Secondary |
| Chronic Myeloid Leukaemia |
27.1% |
| Acute Lymphocytic Leukaemia |
25.1% |
| Product Used For Unknown Indication |
19.4% |
| Drug Use For Unknown Indication |
5.3% |
| Acute Myeloid Leukaemia |
4.3% |
| Prophylaxis |
3.5% |
| B Precursor Type Acute Leukaemia |
2.2% |
| Lung Adenocarcinoma |
2.1% |
| Chromosome Analysis Abnormal |
1.6% |
| Glioblastoma Multiforme |
1.6% |
| Pain |
1.2% |
| Bone Marrow Conditioning Regimen |
1.0% |
| Leukaemia |
0.9% |
| Lymphocytic Leukaemia |
0.9% |
| Lymphoma |
0.8% |
| Systemic Mastocytosis |
0.7% |
| Acute Lymphocytic Leukaemia Recurrent |
0.6% |
| Precursor B-lymphoblastic Lymphoma |
0.6% |
| Acute Leukaemia |
0.5% |
| Breast Cancer Metastatic |
0.5% |
|
| White Blood Cell Count Decreased |
15.6% |
| Pleural Effusion |
10.4% |
| Thrombocytopenia |
8.9% |
| Renal Failure Acute |
7.3% |
| Pyrexia |
5.7% |
| Dyspepsia |
4.2% |
| Lymphopenia |
4.2% |
| Nausea |
4.2% |
| Death |
3.6% |
| Dyspnoea |
3.6% |
| Sepsis |
3.6% |
| Upper Limb Fracture |
3.6% |
| Aspartate Aminotransferase Increased |
3.1% |
| Breast Cancer |
3.1% |
| Escherichia Urinary Tract Infection |
3.1% |
| Febrile Neutropenia |
3.1% |
| Lipids Increased |
3.1% |
| Multi-organ Failure |
3.1% |
| Pyelocaliectasis |
3.1% |
| Shock Haemorrhagic |
3.1% |
|
| Concomitant |
| Chronic Myeloid Leukaemia |
52.3% |
| Prophylaxis |
9.7% |
| Acute Lymphocytic Leukaemia |
5.7% |
| Product Used For Unknown Indication |
5.3% |
| Iron Overload |
3.8% |
| Rash |
3.8% |
| Hypertension |
3.2% |
| Acute Myeloid Leukaemia |
2.3% |
| Prophylaxis Against Graft Versus Host Disease |
2.3% |
| Autoimmune Thyroiditis |
1.3% |
| Interstitial Lung Disease |
1.3% |
| Syncope |
1.3% |
| Urosepsis |
1.3% |
| Bone Marrow Conditioning Regimen |
1.1% |
| Myocardial Ischaemia |
1.1% |
| Nausea |
1.1% |
| Stem Cell Transplant |
1.1% |
| Antiviral Prophylaxis |
0.8% |
| Blast Crisis In Myelogenous Leukaemia |
0.8% |
| Cervix Carcinoma |
0.8% |
|
| Liver Disorder |
9.1% |
| White Blood Cell Count Decreased |
9.1% |
| Haemoglobin Decreased |
6.1% |
| Rash |
6.1% |
| Syncope |
6.1% |
| Thrombocytopenia |
6.1% |
| Vomiting |
6.1% |
| White Blood Cell Count Increased |
6.1% |
| Platelet Count Decreased |
5.1% |
| Death |
4.0% |
| Diarrhoea |
4.0% |
| Drug Ineffective |
4.0% |
| Drug Intolerance |
4.0% |
| Nausea |
4.0% |
| Neoplasm Malignant |
4.0% |
| Weight Increased |
4.0% |
| Chronic Myeloid Leukaemia |
3.0% |
| Hyperbilirubinaemia |
3.0% |
| Malaise |
3.0% |
| Rash Papular |
3.0% |
|
| Interacting |
| B Precursor Type Acute Leukaemia |
21.2% |
| Acute Myeloid Leukaemia |
18.2% |
| Chronic Myeloid Leukaemia |
12.1% |
| Crohn's Disease |
12.1% |
| Pain |
12.1% |
| Anxiety Disorder |
6.1% |
| Nausea |
6.1% |
| Oedema |
6.1% |
| Vomiting |
6.1% |
|
| Renal Failure |
28.6% |
| Cerebellar Syndrome |
14.3% |
| Dysarthria |
14.3% |
| Intestinal Obstruction |
14.3% |
| Intestinal Stenosis |
14.3% |
| Personality Change |
14.3% |
|
